In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
Marie‐Julie Nokin(Université de Bordeaux), David Santamarı́a(Université de Bordeaux)
Cited by 20
Related Papers
RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade
|Nature Communications|2024|54